Olmesartan lowered mean systolic and diastolic blood pressure more significantly than did telmisartan.
Introduction
Patients with type-2 diabetes are at high risk for developing cardiovascular diseases, which are also the most common cause of death in these patients. In type-2 diabetes, the prevalence of hypertension is higher than in the general population ( 1 ) . Hypertension complicated with diabetes increases the incidence of cardiovascular disease ( 2 ) . Thus, to reduce cardiovascular events in patients with type-2 diabetes, treatment of hypertension in addition to glycemic control is important ( 2 , 3 ) . The importance of strict blood pressure control in patients with type-2 diabetes was emphasized in the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) ( 4 ). The report recommends a blood pressure target of < 140/90 mmHg for most patients with uncomplicated hypertension. On the other hand, the report and the Japanese Soci-ety of Hypertension ( 5 ) also recommends < 130/80 mmHg for hypertensive patients with diabetes mellitus.
Angiotensin II type-1 receptor blockers (ARB) are widely used for the treatment of hypertension ( 6 ) . They also have beneficial effects on hypertension-related cardiovascular endorgan damage, at least in part through a reduction of oxidative stress and inflammation ( 7 , 8 ) . In addition, they substantially lower the risk of type-2 diabetes compared with other antihypertensive therapies, probably by regulating insulin sensitivity ( 9 , 10 ) .
Among the several ARBs available in the clinical setting, olmesartan is thought to have a significantly stronger blood pressure lowering effect than losartan or valsartan with their respective starting doses ( 11 , 12 ) . In addition, recent data demonstrated that olmesartan more adequately achieved ambulatory blood pressure monitoring (ABPM) goals during the early morning surge period than did candesartan ( 13 ) . Considering the importance of strict blood pressure control ( 14 ) , olmesartan offers certain advantages in clinical use.
With regard to its metabolic effect, telmisartan has the unique property of selective peroxisome proliferation-activated receptor γ (PPAR γ )-modulating activity, at least in vitro ( 15 -17 ) . Thus, telmisartan might have clinical effects similar to those of PPAR γ agonists, such as improving insulin resistance and increasing serum adiponectin levels. In fact, a recent study demonstrated that replacement of valsartan with telmisartan reduced serum highly sensitive C-reactive protein (hs-CRP) and increased serum adiponectin ( 18 ) . Another study revealed that telmisartan has superior effects on metabolic parameters compared to losartan in hypertensive patients with metabolic syndrome ( 19 ) . In addition, telmisartan's blood pressure lowering effect is reported to last longer than valsartan's ( 20 ) .
To gain insight into the respective properties of ARB for type-2 diabetic patients with hypertension, an open-label crossover trial was conducted to compare the efficacy of the starting doses of olmesartan and telmisartan on blood pressure, metabolic parameters, and inflammatory parameters.
Methods

Subjects
All patients with type-2 diabetes mellitus who visited Juntendo University Hospital (Tokyo, Japan) or Secomedic Hospital (Funabashi, Japan) from March 2006 to August 2006 were asked to participate in the study. The inclusion criteria were patients with type-2 diabetes mellitus and hypertension who were being treated with valsartan 80 mg once daily for at least 8 weeks. Patients with HbA1c exceeding 7.0% and/or patients treated with insulin or more than a minimal dose of sulfonylurea agents were excluded from the study. In addition, patients with diabetic microangiopathy, severe renal or hepatic disease, overt cardiovascular disease, or malignancy were excluded. A total of 20 Japanese subjects were recruited for this study. The hospital ethics committee approved this study protocol, and informed consent was obtained from each subject.
Study Design
An open-label crossover design was used. After completion Fig. 1 of a run-in period consisting of once-daily administration of valsartan 80 mg, blood pressure during a 24-h interval was monitored with ABPM, and fasting blood samples were collected. The participants were then randomized into one of two treatment groups who received either 20 mg olmesartan medoxomil or 40 mg telmisartan once daily in the morning instead of valsartan. After 8 weeks of olmesartan/telmisartan treatment, blood pressure was again monitored with ABPM and fasting blood samples were collected. Then, the subjects on olmesartan were switched to telmisartan and those on telmisartan were switched to olmesartan. This treatment was given for 8 weeks, after which another ABPM was performed with fasting blood sampling ( Fig. 1 ). All subjects were advised to consume their usual diet during the study period. Each patient was reviewed for general health and compliance with medication, which was assessed by tablet counts and checking of blood pressure, body weight, diet, and exercise status at each visit. During this study period the medication was not altered except for ARBs. The clinical characteristics of the study patients are listed in Table 1 .
Definition of Metabolic Syndrome
We used the definition proposed by the Japanese Society of Internal Medicine (JSIM). Participants who had obesity (waist: male ≥ 85 cm, female ≥ 90 cm) plus at least two of the following three components were defined as JSIM-MS (metabolic syndrome): 1) high-density lipoprotein (HDL) cholesterol ≤ 1.036 mmol/L or triglyceride ≥ 1.695 mmol/L or medication for hyperlipidemia, 2) fasting glucose ≥ 6.10 mmol/L or medication for diabetes; 3) blood pressure ≥ 130/ 85 mmHg or taking an antihypertensive.
Biochemical Measurements
Blood samples were obtained between 8:00 and 10:00 after overnight fasting. Serum lipids (total cholesterol, HDL cholesterol, low-density lipoprotein [LDL] cholesterol, and triglycerides), glucose, and HbA1c were measured with standard techniques. Insulin, high-sensitivity interleukin (IL)-6, high-sensitivity intercellular adhesion molecule (ICAM)-1, high-sensitivity vascular cell adhesion molecule (VCAM)-1, IL-18, and adiponectin were measured by enzyme immunoassay, and hs-CRP was measured by latex nephelometry, both in a private laboratory (BML Laboratory, Chiba, Japan). The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated as the product of fasting plasma insulin ( μ U/mL) and fasting plasma glucose level (mmol/L) divided by 22.5.
ABPM
Ambulatory blood pressure monitors (A&D Company, Tokyo, Japan) were used for 24-h ABPM. On the day of ABPM, study medication was administered as close to 8:00 as possible and about 24 h after the previous medication. After the ABPM device was attached, blood pressure was recorded every 60 min. The device was removed after a minimum of 24 h of recording. The daytime (7:00-22:00) and nighttime (0:00-6:00) ABPM were also defined as previously reported ( 21 ) .
Statistical Analysis
Two-way analysis of variance (ANOVA) was used to compare demographic and laboratory parameters between the olmesartan-and telmisartan-treatment groups. To approximate normal distribution, natural log-transformed values for IL-6 and IL-18 were used in the analysis, and were reported as the geometric means and 95% confidence intervals (CI) for those means. ANOVA was used to analyze the ABPM data of the olmesartan-and telmisartan-treated groups. All statistical tests were two-sided with a 5% significance level. Data are presented as mean ± SD.
Results
All enrolled patients ( n = 20) completed the trial. The demographic characteristics and mean baseline data are shown in Tables 1-3 . The subjects were relatively obese (body mass index [BMI] 25.6 ± 1.1 kg/m 2 ), and their rate of metabolic syndrome was 65%. Their blood glucose, blood pressure, and lipid data were well controlled. Figure 2 shows the mean hourly systolic and diastolic blood pressures, and Table 2 shows the mean blood pressure analyzed by 24-h ABPM. The recommended target blood pres- 
n = 20. Data are mean ± SD or number of subjects.
sure level (< 130/80 mmHg) was achieved in 8, 9, and 7 cases during valsartan, olmesartan, and telmisartan treatment, respectively. Olmesartan reduced systolic, diastolic, and mean blood pressure by 3.3, 2.7, and 3.1 mmHg more than did telmisartan, respectively; these were statistically significant differences. Similarly, olmesartan significantly reduced diastolic and mean blood pressure during the daytime by 3.2 and 3.1 mmHg, and reduced systolic, diastolic, and mean blood pressure during the nighttime by 5.4, 3.3, and 4.0 mmHg, respectively, more than telmisartan did; these differences between treatments were statistically significant. The metabolic markers, including HbA1c, HOMA-IR, and serum adiponectin, were comparable between the two treatments. On the other hand, among the inflammation markers investigated in the present study, IL-6 and hs-CRP were reduced by olmesartan significantly more than the reduction by telmisartan.
Discussion
Our data demonstrated that olmesartan at 20 mg/day had more potent blood pressure lowering and anti-inflammatory effects than telmisartan at 40 mg/day. Although recent data demonstrated that telmisartan has unique PPAR γ -modulating activity ( 15 -17 ) , the metabolic parameters during each treatment were comparable. In this study, we compared the blood pressure lowering effects of each ARB by 24-h ABPM. With regard to mean Data are mean±SD. *p values by ANOVA for differences between data of the olmesartan and telmisartan groups. HDL, high-density lipoprotein; LDL, low-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; VCAM-1, vascular cell adhesion molecule; ICAM-1, intercellular adhesion molecule-1; hs-CRP, highly sensitive C-reactive protein; n.s., not significant.
blood pressure on a particular day, olmesartan was significantly more effective than telmisartan at reducing systolic, diastolic, and mean blood pressure. Recently, several large trials showed that strict blood pressure control could reduce the onset of cardiovascular disease in patients with type-2 diabetes (2, 3, 22) . For example, a 4 mmHg fall in diastolic blood pressure in the Hypertension Optimal Treatment (HOT) study was equated with a 51% decrease in the onset of cardiovascular disease (2) . Similarly, a 1.92 mmHg decrease in systolic blood pressure in the Heart Out-comes Prevention Evaluation (HOPE) study was equated with a 25% reduction in cardiovascular mortality in type-2 diabetic patients (3, 22) . Therefore, the fall in arterial pressure recorded in our study was more than a subtle change. In addition, olmesartan therapy reduced mean systolic and diastolic blood pressure to below 130/80 mmHg, which is recommended by JNC 7 (4) and ESH/ESC (23).
After adjustment for classic risk factors, the increases in 24-h daytime (8:00-20:00) and nighttime (0:00-6:00) ambulatory blood pressure were associated with cardiovascular events (24) . While olmesartan and telmisartan are regarded as ARBs with a longer duration of action (13, 25) , olmesartan significantly reduced both daytime and nighttime mean blood pressure levels compared with telmisartan. These results suggest that the superiority of olmesartan's blood pressure lowering effect might depend on its strength rather than on the duration of its pharmacological action.
In addition to their beneficial effects on lowering blood pressure, ARBs have anti-atherogenic effects by blocking angiotensin II, which promotes oxidative stress, inflammation, vasoconstriction, and thrombosis (7, 8) , as well as antidiabetic effects by regulating insulin sensitivity (9, 10, 26) . In this study, we evaluated the effects of olmesartan and telmisartan on inflammatory markers. Several recent studies have demonstrated that olmesartan, but not telmisartan, reduces serum IL-6 level (27) (28) (29) . In agreement with these data, we also found that serum hs-CRP and IL-6 levels were significantly lower by olmesartan than by telmisartan treatment. Angiotensin II is known as one of the main effector peptides inducing IL-6 expression in vascular smooth muscle cells (30, 31) . In addition, it is well known that IL-6 induces CRP expression. Because ARB's blood pressure lowering effect seems to parallel the effect of angiotensin II blocking, it is conceivable that olmesartan, a stronger ARB, can reduce serum IL-6 level more efficiently than telmisartan.
Recent studies suggest that telmisartan, but not other ARBs, could act as a partial PPARγ agonist (15) (16) (17) . Since PPARγ plays an important role in the regulation of insulin sensitivity, at least in part by increasing serum adiponectin level (32, 33) , telmisartan might have a preferable effect on patients with diabetes. In a 3-month study comparing telmisartan 80 mg and losartan 50 mg in hypertensive patients with metabolic syndrome, only telmisartan improved blood glucose level and insulin sensitivity (19) . Here, we compared the effects of olmesartan and telmisartan on various metabolic parameters. However, our results showed no differences in metabolic parameters, including serum adiponectin level, between telmisartan and olmesartan. It is not clear why telmisartan did not change metabolic parameters in our study. We used a starting dose of telmisartan (40 mg/day) for 8 weeks. It is possible that a higher dose and/or longer administration may be required to observe the unique metabolic effect of telmisartan. In addition, baseline HOMA-IR in the present study was smaller than in the previous study that showed telmisartan's clinical effect on insulin sensitivity (19) . It might be difficult to observe the metabolic effect of telmisartan in subjects with low insulin resistance. In fact, recent data demonstrated that telmisartan has a neutral effect on insulin resistance in hypertensive metabolic syndrome with relatively low HOMA-IR (34) . However, the gold standard of insulin sensitivity measurement is the hyperinsulinemic euglycemic glucose clamp method. Further studies are needed to assess the effect of telmisartan on insulin resistance by hyperinsulinemic euglcyemic glucose clamp. It is noteworthy that other studies reported that telmisartan improves glycemic control and insulin sensitivity without affecting serum adi- (35) (36) (37) . In rats fed a high-fat, high-carbohydrate diet, telmisartan treatment promoted increases in caloric expenditure and protected against dietary-induced weight gain (38) . They demonstrated that these findings may be due to the increased expression of genes for regulating mitochondrial function and energy metabolism (17) in skeletal muscle, suggesting that this effect does not necessarily depend on adiponectin's effect. Thus, it is possible that telmisartan improves insulin sensitivity without affecting serum adiponectin level also in the clinical setting.
In conclusion, at clinical doses in patients with type-2 diabetes, olmesartan seems to have more potent blood pressure lowering and anti-inflammatory effects than telmisartan, but similar effects on metabolic parameters. Our results suggest that olmesartan can be considered an ideal agent to prevent future onset of cardiovascular disease in type-2 diabetic patients with hypertension.
